Abstract

MO50-4 Efficacy and safety of commercially approved BCMA-targeting CAR-T therapy in triple-class refractory multiple myeloma

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call